New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life CARLSBAD, Calif., and CAMBRIDGE, Mass., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS... Biopharmaceuticals, Neurology Ionis Pharmaceuticals, Akcea Therapeutics, TEGSEDI, inotersen, hATTR
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news